Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$49.20
+1.4%		$54.95
$19.65
▼
$72.36
$1.45B0.76542,479 shs595,547 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$14.66
+12.5%		$12.17
$5.50
▼
$24.17
$370.35M2.48766,806 shs1.32 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$94.56
-2.5%		$103.03
$28.16
▼
$155.29
$1.43B3.81351,670 shs206,869 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$4.49
-3.0%		$5.60
$3.69
▼
$7.30
$1.51B1.194.09 million shs4.97 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
0.00%-4.84%-14.56%-22.12%+56.85%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%-5.92%-17.64%+77.28%-42.24%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%-2.63%-19.96%-0.15%+172.06%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.00%-0.86%-17.32%-27.43%-2.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$49.20
+1.4%		$54.95
$19.65
▼
$72.36
$1.45B0.76542,479 shs595,547 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$14.66
+12.5%		$12.17
$5.50
▼
$24.17
$370.35M2.48766,806 shs1.32 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$94.56
-2.5%		$103.03
$28.16
▼
$155.29
$1.43B3.81351,670 shs206,869 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$4.49
-3.0%		$5.60
$3.69
▼
$7.30
$1.51B1.194.09 million shs4.97 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
0.00%-4.84%-14.56%-22.12%+56.85%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%-5.92%-17.64%+77.28%-42.24%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%-2.63%-19.96%-0.15%+172.06%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.00%-0.86%-17.32%-27.43%-2.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.71
Moderate Buy$77.7958.10% Upside
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2.64
Moderate Buy$22.4352.99% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.50
Moderate Buy$197.50108.86% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$12.77184.39% Upside

Current Analyst Ratings Breakdown

Latest ARCT, ANAB, TSHA, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$70.00 ➝ $60.00
9/24/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/24/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$23.00 ➝ $20.00
9/24/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$8.00 ➝ $20.00
9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$90.00 ➝ $81.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/17/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/11/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M6.27N/AN/A$1.34 per share36.72
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$82.03M5.08N/AN/A$7.53 per share1.95
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.30M1,070.71N/AN/A$0.55 per share171.93
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$9.77M149.74N/AN/A$0.90 per share4.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$5.379.1641.34N/A82.37%112.00%2.20%11/3/2026 (Estimated)
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$65.78M-$3.31N/AN/AN/A-317.62%-46.54%-36.46%11/9/2026 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.88N/AN/AN/AN/A-563.90%-83.48%11/13/2026 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$109M-$0.42N/AN/AN/AN/A-56.19%-41.84%11/3/2026 (Estimated)

Latest ARCT, ANAB, TSHA, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
8/13/2026Q2 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.28-$2.34-$0.06-$2.34N/AN/A
8/11/2026Q2 2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.1133-$0.13-$0.0167-$0.13$0.68 millionN/A
8/7/2026Q2 2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$0.9964-$0.84+$0.1564-$0.84$3.11 million$2.96 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
5.88
5.88
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
5.07
5.07
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.13
17.76
17.76

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
17.80%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.90 million20.48 millionOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
11128.42 million23.36 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
11014.72 million12.03 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
99325.83 million314.50 millionOptionable

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.4% - Time to Sell?
October 5 at 1:01 PM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088251
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 5.4% - Should You Sell?
October 5 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-taysha-gene-therapies-nasdaq-tsha-shares-down-54-should-you-sell-2026-10-05/
Analyzing Amylyx Pharmaceuticals (NASDAQ:AMLX) and Taysha Gene Therapies (NASDAQ:TSHA)
October 5 at 3:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085810
Head to Head Analysis: Artiva Biotherapeutics (NASDAQ:ARTV) vs. Taysha Gene Therapies (NASDAQ:TSHA)
October 4 at 12:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085302
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 4 at 12:11 AM  |  biospace.comB
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 2 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373768/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372824/0/en/taysha-gene-therapies-announces-multiple-encore-presentations-supporting-tsha-102-rett-syndrome-clinical-program-at-the-55th-child-neurology-society-annual-meeting.html
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-taysha-gene-therapies-nasdaq-tsha-shares-up-57-heres-what-happened-2026-09-28/
Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-taysha-gene-therapies-nasdaq-tsha-earns-outperform-rating-from-analysts-at-wolfe-research-2026-09-17/
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-taysha-gene-therapies-inc-nasdaq-tsha-receives-average-recommendation-of-buy-from-analysts-2026-09-12/
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945540-taysha-gene-therapies-a-bull-case-that-does-not-require-the-fastest-approval
Illustration of an industrial facility with a glowing upward arrow chart line overlaid against a city skyline at dusk.
These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)
...
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/these-3-risky-stocks-could-be-sitting-on-100-upside/
Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-acquires-3349244-shares-of-taysha-gene-therapies-inc-tsha-2026-09-06/
Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-new-position-in-taysha-gene-therapies-inc-tsha-2026-09-06/
Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-has-994-million-holdings-in-taysha-gene-therapies-inc-tsha-2026-09-05/
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356521/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Taysha Gene Therapies Earnings Call Highlights Pivotal Progress
August 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/taysha-gene-therapies-earnings-call-highlights-pivotal-progress?utm_source=marketbeat.com&utm_medium=referral
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-tsha-q2-231331648.html
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TSHA/pressreleases/3824580/wells-fargo-issues-a-buy-rating-on-taysha-gene-therapies-tsha/
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-tsha-rett-140937044.html
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69283092-taysha-gene-therapies-inc-taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Illustration of an industrial facility with a glowing upward arrow chart line overlaid against a city skyline at dusk.
These 3 Risky Stocks Could Be Sitting on 100% Upside
By Nathan Reiff | September 7, 2026
Inhibrx logo overlaid on a laboratory scene with vials, pipettes, and a computer screen showing a protein model.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
By Jeffrey Neal Johnson | October 2, 2026
AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$49.20 +0.67 (+1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$49.20 -0.01 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$14.66 +1.63 (+12.51%)
Closing price 04:00 PM Eastern
Extended Trading
$14.62 -0.04 (-0.29%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$94.56 -2.43 (-2.51%)
Closing price 04:00 PM Eastern
Extended Trading
$94.85 +0.29 (+0.30%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$4.49 -0.14 (-3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$4.49 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas